Comprehensive Clinical Evaluation Study of GLP-1RA
NCT06686134 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 492
Last updated 2024-11-13
Summary
The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In accordance with the index system and evaluation rules set forth in the Management Guidelines for Comprehensive Clinical Evaluation of Drugs, the effects of GLP-1RAs drugs in real-world settings are tracked, summarised, and analysed across six dimensions: safety, effectiveness, economy, innovation, appropriateness, and accessibility. This is done with the objective of ensuring that these drugs are fully utilised in accordance with their potential benefits. The objective is to ascertain the role of medical institutions as the principal entity responsible for the comprehensive evaluation of the clinical application of drugs and to provide data that will reduce the risk of using GLP-1RAs drugs. Moreover, the objective is to ascertain the advantages of their clinical application and to guarantee the safe and rational use of drugs for patients with type 2 diabetes mellitus. The objective of this study is to facilitate the fulfilment of medical institutions' role as the primary entity responsible for the comprehensive evaluation of the clinical application of medicines. Furthermore, the study will provide data that can be used to reduce the risk of using GLP-1RAs drugs, explore the advantages of their clinical application, and guarantee the safe and rational use of medicines for patients with type 2 diabetes.
Conditions
- T2DM
Sponsors & Collaborators
-
LI YAN
lead OTHER
Principal Investigators
-
Yining Dong, pharmacist · Shandong Third Hospital
-
Zhongming Wu, doctor · Endocrine and Metabolic Disease Hospital of Shandong First Medical University
-
Yue Liu, pharmacist · Shandong University of Traditional Chinese Medicine
-
Dandan Wu, pharmacist · Affiliated Hospital of Binzhou Medical College
-
Jing Peng, pharmacist · Jining Medical University
-
Qi Wang, pharmacist · Jinan Fifth People's Hospital
-
Zhaohui Meng, pharmacist · Jinan Laiwu People's Hospital
-
Dong wei Wang, doctor · Jinan Mental Health Center
-
Zhong Yuan, pharmacist · Jinan Municipal Hospital
-
Ming Xue, pharmacist · Jinan Hospital, Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, China
-
Jing Lin, pharmacist · Shijhong District People's Hospital
-
Xingshan Wang, doctor · Changqing District Hospital of Traditional Chinese Medicine
-
Min Fan, pharmacist · Pingyin County People's Hospital
-
Xue Zheng, pharmacist · Zibo Center Hospital
-
Ming Xu, pharmacist · Zibo First Hospital
-
Yan Song, pharmacist · Zibo Municipal Hospital
-
Ruoxun Liu, pharmacist · Zibo Hospital of Traditional Chinese Medicine
-
Qing Zhao, doctor · Linzi District Maternal and Child Health Center
-
Zhenwei Chen, pharmacist · Yiyuan County People's Hospital
-
Zhiyan Li, pharmacist · Zaozhuang Municipal Hospital
-
Shenling Cheng, pharmacist · Tengzhou Central People's Hospital
-
Qixia Zhao, pharmacist · Zaozhuang Shanting District People's Hospital
-
Jintang Ning, pharmacist · Dongying People's Hospital
-
Juying Ding, pharmacist · Shengli Oilfield Hospital
-
Jiaxi Jiang, pharmacist · Haiyang People's Hospital
-
Guichun Wang, pharmacist · Longko People's Hospital
-
Zhentian Cheng, pharmacist · Weifang Yidu Center Hospital
-
Yueliang Ji, doctor · Fangzi District People's Hospital
-
Donglou Liang, pharmacist · Jining First People's Hospital
-
Li Zhang, pharmacist · QuFu People's Hospital
-
Guifeng Tan, doctor · Wenshang County People's Hospital
-
Ronghua Wang, pharmacist · Weihai Maternal and Child Health Center
-
Jianfang Liu, pharmacist · Rizhao People's Hospital
-
Xiangju Tian, doctor · Linyi Hospital of Traditional Chinese Medicine
-
Pengcheng Du, pharmacist · Shandong University Qilu Hospital, Dezhou Hospital
-
Fujian Xu, pharmacist · Heze Municipal Hospital
-
Deping Ho, pharmacist · Heze Third People's Hospital
-
Jingyong Xue, pharmacist · Heze Mudan People's Hospital
-
Lishun Yin, pharmacist · Heze Dingtao District People's Hospital
-
Shengmei Wei, pharmacist · Caoxian People's Hospital
-
Jing Meng, pharmacist · Shanxian Central Hospital
-
Ye Fan, pharmacist · Yuncheng County People's Hospital
-
Jingjing Zhang, pharmacist · Qingdao Eighth People's Hospital
-
Wenqian Han, pharmacist · Tai'an Central Hospital
-
Wenwen Lv, pharmacist · Affiliated Hospital of Binzhou Medical College
-
Tao Geng, pharmacist · The Second Affiliated Hospital of Shandong First Medical University
-
Fang Liu, pharmacist · Shengli Oilfield Hospital
-
Congrong Wang, pharmacist · Shandong Public Health Clinical Center
-
Ping Wang, pharmacist · Tengzhou Central People's Hospital
-
Yuxia Gao, pharmacist · Dongying Hospital Affiliated to Shandong University of Traditional Chinese Medicine (Dongying Hospital of Traditional Chinese Medicine)
-
Bo Liu, pharmacist · Qingdao Central Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2025-12-31
- Completion
- 2026-07-31
Countries
- China
Study Locations
More Related Trials
-
Effects of GLP-1 on Chronic Heart Failure
NCT02650596 ·Status: UNKNOWN ·Phase: NA
-
GLP-1 REceptor Agonists and Real World EvIdeNce
NCT03959865 ·Status: UNKNOWN
-
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
NCT07314684 ·Status: RECRUITING ·Phase: PHASE4
-
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
NCT02255266 ·Status: COMPLETED
-
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609 ·Status: COMPLETED ·Phase: NA
-
Effect of Liraglutide on Clock Genes
NCT02783196 ·Status: UNKNOWN ·Phase: NA
-
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
NCT01509742 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
NCT02490176 ·Status: UNKNOWN ·Phase: NA
-
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664 ·Status: COMPLETED ·Phase: PHASE3
-
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
NCT05297045 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT06976619 ·Status: RECRUITING ·Phase: PHASE2
-
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
NCT01790308 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Glucagon Like Peptide-1 on No-reflow
NCT02507128 ·Status: UNKNOWN ·Phase: NA
-
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects
NCT00884091 ·Status: COMPLETED
-
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287 ·Status: UNKNOWN ·Phase: PHASE4
-
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
NCT01722227 ·Status: WITHDRAWN ·Phase: PHASE3
-
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
NCT01722266 ·Status: COMPLETED ·Phase: PHASE3
-
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603 ·Status: UNKNOWN ·Phase: NA
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
NCT06338553 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
NCT06818292 ·Status: COMPLETED ·Phase: NA
-
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
NCT07141472 ·Status: COMPLETED ·Phase: NA
-
Liraglutide in Type 1 Diabetes
NCT01612468 ·Status: COMPLETED ·Phase: PHASE4